Physician profile
Sameer Bhalla
NPI 1962066365
$3,211.84
in general payments reported to CMS, 2019-2025
18 companies · $2,376 in 2025
The $2,376 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $836 · 2025: $2,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.84 |
| Education | $183.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| 3-D Matrix, INC. | $610.81 | 2025 | |
| Abbvie INC. | $562.76 | 2024-2025 | |
| Janssen Biotech, INC. | $420.22 | 2024-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $355.20 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $232.86 | 2024-2025 | Entyvio |
| Madrigal Pharmaceuticals | $217.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.68 | 2025 | Xifaxan, Trulance |
| Intercept Pharmaceuticals, INC. | $140.47 | 2024-2025 | |
| Genzyme Corporation | $117.52 | 2024-2025 | |
| Celltrion USA INC. | $102.22 | 2025 | Vegzelma |
| Pfizer INC. | $83.00 | 2025 | |
| Vivus LLC | $45.10 | 2024-2025 | Qsymia |
| Novo Nordisk INC | $41.63 | 2025 | Wegovy |
| Lilly USA, LLC | $33.26 | 2025 | Omvoh |
| Daiichi Sankyo INC. | $26.97 | 2024 | Injectafer |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $21.53 | 2024 | Elzonris |
| Phathom Pharmaceuticals, INC. | $21.13 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $16.40 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.